πŸ‡ΊπŸ‡Έ FDA
Patent

US 11352389

Treatment of haematological malignancies

granted A61KA61K2039/525A61K2039/53

Quick answer

US patent 11352389 (Treatment of haematological malignancies) held by Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Academisch Ziekenhuis Leiden h.o.d.n. Leids Universitair Medisch Centrum
Grant date
Tue Jun 07 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/525, A61K2039/53, A61K2039/572, A61K2039/585